Simulations Plus
Builds drug-development simulation software and consulting services for biopharma clients.
Something off on this page? Send us feedback.
Profile
Sells model-informed drug development software and specialist consulting through Software and Services segments. Revenue is concentrated in the Americas, with EMEA and Asia Pacific customers, and the business depends on biopharma R&D spending, regulated drug-development workflows, and competition from scientific software providers, CROs, in-house teams, academia, and open-source tools.
Builds model-informed drug development tools used across discovery, clinical research, trial operations, regulatory work, and commercialization. Software centers on GastroPlus, ADMET Predictor, and MonolixSuite, while Services covers PKPD, PBPK, QSP/QST, and regulatory strategy consulting.
Commercial activity is concentrated in the Americas, with additional EMEA and Asia Pacific customers. The company is headquartered in Research Triangle Park, operates with a remote-work model, and has added clinical-training and QSP capabilities through acquisitions.
Execution depends on scientific credibility, product renewal, expert consulting capacity, and biopharma client spending. Competition includes specialist software vendors, CROs, in-house client teams, academic and government groups, open-source alternatives, and fast-moving AI/ML tools.
Company facts
Categories
Key statistics
Year to date +1.6% · Average volume (30d) 310.3K
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Jun 18, 2026 | Craig-Hallum | Target | $56 | $18.50 | ||
| Jun 17, 2026 | William Blair | Downgrade | Outperform | Market Perform | ||
| Dec 18, 2025 | BTIG | Downgrade | Buy | Neutral | ||
| Jul 15, 2025 | Keybanc | Downgrade | Overweight | Sector Weight |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Jul 9, 2026Q3 FY26 | $0.23 | $0.30 | +29.0% | $20.9M | $21.9M | +4.7% | −0.55% |
| Apr 9, 2026Q2 FY26 | $0.27 | $0.35 | +29.6% | $21.7M | $24.3M | +12.2% | +0.38% |
| Jan 8, 2026Q1 FY26 | $0.18 | $0.13 | −27.8% | $18.1M | $18.4M | +2.0% | +8.59% |
| Dec 1, 2025Q4 FY25 | $0.10 | $0.10 | 0.0% | $17.4M | $17.5M | +0.4% | +14.14% |
Financial highlights
| 12 quarters | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $22.4M | $20.4M | $17.5M | $18.4M | $24.3M | $21.9M | |
| Gross profit | $13.1M | $13.0M | $9.8M | $10.9M | $16.1M | $15.1M | |
| Operating income | $2.7M | −$74.2M | $659.0K | $713.0K | $5.6M | $4.5M | |
| Net income | $3.1M | −$67.3M | −$681.0K | $676.0K | $4.5M | $3.6M | |
| Diluted EPS | $0.15 | −$3.35 | −$0.03 | $0.03 | $0.22 | $0.18 | |
| Gross margin | 58.5% | 64.0% | 56.4% | 59.1% | 66.5% | 69.1% | |
| Operating margin | 12.1% | -364.5% | 3.8% | 3.9% | 23.2% | 20.6% |
Fiscal years (4-quarter sums)FY21 $46.5M · FY22 $53.9M · FY23 $59.6M · FY24 $70.0M · FY25 $79.2M
Revenue by product · Q3 FY26
Revenue by geography · Q3 FY26
Balance sheet, May 31, 2026Cash & short-term investments $50.0M · Total debt $487.0K · Total assets $153.0M · Shareholders' equity $139.0M
Dividends
Raised for 11 straight years.
History
| Ex-date | Record | Paid | Amount | Note |
|---|---|---|---|---|
| Jul 29, 2024 | Jul 29 | Aug 5 | $0.06 | |
| Apr 26, 2024 | Apr 29 | May 6 | $0.06 | |
| Jan 26, 2024 | Jan 29 | Feb 5 | $0.06 | |
| Oct 27, 2023 | Oct 30 | Nov 6 | $0.06 | |
| Jul 28, 2023 | Jul 31 | Aug 7 | $0.06 | |
| Apr 21, 2023 | Apr 24 | May 1 | $0.06 | |
| Jan 27, 2023 | Jan 30 | Feb 6 | $0.06 | |
| Oct 28, 2022 | Oct 31 | Nov 7 | $0.06 |
Ownership
Shares outstanding 20.22M · Float 16.81M · 83.1% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| Walter S. Woltosz · director, 10 percent owner: | 3.20M | 15.83% | Form 4 | Jul 6, 2026 |
| First Light Asset Management, LLC | 2.79M | 13.81% | 13F | Aug 14, 2026 |
| Conestoga Capital Advisors | 2.40M | 11.95% | 13G | Jan 10, 2025 |
| BlackRock, Inc. | 1.50M | 7.43% | 13F | Aug 7, 2026 |
| First Eagle Investment Management, LLC | 1.07M | 5.29% | 13F | Aug 24, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 3, 2026 | John Anthony II DiBella | officer: Chief Revenue Officer | −1,000 | $18.28 |
| Jul 6, 2026 | John Anthony II DiBella | officer: Chief Revenue Officer | −1,000 | $18.36 |
| Jul 1, 2026 | Walter S. Woltosz | director, 10 percent owner: | −4,177 | $18.44 |
| Jun 16, 2026 | Jill Fiedler-Kelly | officer: President, Services Solutions | −7,350 | $18.20 |
| Jun 15, 2026 | Jill Fiedler-Kelly | officer: President, Services Solutions | −1,050 | $16.51 |
Peers
- Certara
Closest public MIDD software and biosimulation-services peer
- Schrödinger
Physics-based molecular design software for early drug discovery
- IQVIA
Scale CRO and healthcare-intelligence peer for clinical workflows
- ICON
Global CRO peer for clinical development and pharmacology services
- Thermo Fisher Scientific
PPD-driven CRO and medical-communications overlap
- Revvity
Cheminformatics and scientific-informatics peer in discovery workflows
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Simulations Plus | $18.40 | 0.00% | $371.9M | 46.0 | 21.6 | 4.5 | +7.5% |
| Certara | $8.35 | −0.12% | $1.30B | — | 21.5 | 3.2 | −10.8% |
| Schrödinger | $19.67 | −0.15% | $1.47B | — | — | 5.7 | +7.5% |
| IQVIA | $261.75 | +0.03% | $43.08B | 32.5 | 19.2 | 2.5 | +8.7% |
| ICON | $170.02 | +0.07% | $13.02B | 39.9 | 15.2 | 1.6 | +2.3% |
| Thermo Fisher Scientific | $620.01 | −0.32% | $231.22B | 33.5 | 23.7 | 5.0 | +10.5% |
| Revvity | $127.20 | −1.25% | $14.37B | 61.3 | 22.9 | 4.9 | −1.3% |
| Median | 36.7 | 21.5 | 4.1 | +4.9% |